# Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers

> **NCT04446065** · PHASE2,PHASE3 · UNKNOWN · sponsor: **MELISA Institute Genomics & Proteomics Research SpA** · enrollment: 524 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV2

## Interventions

- **DRUG:** Previfenon®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04446065
- **Lead sponsor:** MELISA Institute Genomics & Proteomics Research SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2020-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446065, "Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04446065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*